These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 18657593

  • 1. Effects of levodopa on striatal monoamines in mice with levodopa-induced hyperactivity.
    Nicholas AP, Buck K, Ferger B.
    Neurosci Lett; 2008 Oct 10; 443(3):204-8. PubMed ID: 18657593
    [Abstract] [Full Text] [Related]

  • 2. Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease.
    Luchtman DW, Shao D, Song C.
    Physiol Behav; 2009 Aug 04; 98(1-2):130-8. PubMed ID: 19410592
    [Abstract] [Full Text] [Related]

  • 3. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP, Fox SH, Johnston T, Reyes G, Millan MJ, Brotchie JM.
    Neurobiol Dis; 2009 Aug 04; 35(2):184-92. PubMed ID: 19118628
    [Abstract] [Full Text] [Related]

  • 4. The MPTP mouse model: cues on DA release and neural stem cell restorative role.
    Serra PA, Pluchino S, Marchetti B, Desole MS, Miele E.
    Parkinsonism Relat Disord; 2008 Aug 04; 14 Suppl 2():S189-93. PubMed ID: 18579428
    [Abstract] [Full Text] [Related]

  • 5. Role of estrogen receptors in neuroprotection by estradiol against MPTP toxicity.
    Morissette M, Jourdain S, Al Sweidi S, Menniti FS, Ramirez AD, Di Paolo T.
    Neuropharmacology; 2007 Jun 04; 52(7):1509-20. PubMed ID: 17420033
    [Abstract] [Full Text] [Related]

  • 6. Interleukine-1beta and interleukine-6 levels in striatum and other brain structures after MPTP treatment: influence of behavioral lateralization.
    Shen YQ, Hebert G, Lin LY, Luo YL, Moze E, Li KS, Neveu PJ.
    J Neuroimmunol; 2005 Jan 04; 158(1-2):14-25. PubMed ID: 15589033
    [Abstract] [Full Text] [Related]

  • 7. Striatal extracellular dopamine levels and behavioural reversal in MPTP-lesioned mice.
    Kirchhoff J, Mørk A, Brennum LT, Sager TN.
    Neuroreport; 2009 Mar 25; 20(5):482-6. PubMed ID: 19262413
    [Abstract] [Full Text] [Related]

  • 8. Levodopa-induced hyperactivity in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Nicholas AP.
    Mov Disord; 2007 Jan 25; 22(1):99-104. PubMed ID: 17133519
    [Abstract] [Full Text] [Related]

  • 9. Widespread Monoaminergic Dysregulation of Both Motor and Non-Motor Circuits in Parkinsonism and Dyskinesia.
    Engeln M, De Deurwaerdère P, Li Q, Bezard E, Fernagut PO.
    Cereb Cortex; 2015 Sep 25; 25(9):2783-92. PubMed ID: 24770706
    [Abstract] [Full Text] [Related]

  • 10. Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease.
    Johnston TH, van der Meij A, Brotchie JM, Fox SH.
    Mov Disord; 2010 Jul 30; 25(10):1379-90. PubMed ID: 20310030
    [Abstract] [Full Text] [Related]

  • 11. Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats.
    Visanji NP, Millan MJ, Brotchie JM.
    Exp Neurol; 2006 Nov 30; 202(1):85-92. PubMed ID: 16814282
    [Abstract] [Full Text] [Related]

  • 12. Neonatal exposure to paraquat or MPTP induces permanent changes in striatum dopamine and behavior in adult mice.
    Fredriksson A, Fredriksson M, Eriksson P.
    Toxicol Appl Pharmacol; 1993 Oct 30; 122(2):258-64. PubMed ID: 8212007
    [Abstract] [Full Text] [Related]

  • 13. Indirubins deplete striatal monoamines in the Intact and MPTP-treated mouse brain and block kainate-induced striatal astrogliosis.
    Magiatis P, Polychronopoulos P, Skaltsounis AL, Lozach O, Meijer L, Miller DB, O'Callaghan JP.
    Neurotoxicol Teratol; 2010 Oct 30; 32(2):212-9. PubMed ID: 20034560
    [Abstract] [Full Text] [Related]

  • 14. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.
    Brain; 2008 Dec 30; 131(Pt 12):3380-94. PubMed ID: 18952677
    [Abstract] [Full Text] [Related]

  • 15. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism.
    Anderson DW, Bradbury KA, Schneider JS.
    Eur J Neurosci; 2008 Aug 30; 28(3):610-7. PubMed ID: 18702732
    [Abstract] [Full Text] [Related]

  • 16. Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Samadi P, Grégoire L, Rouillard C, Bédard PJ, Di Paolo T, Lévesque D.
    Ann Neurol; 2006 Feb 30; 59(2):282-8. PubMed ID: 16437566
    [Abstract] [Full Text] [Related]

  • 17. Striatal histone modifications in models of levodopa-induced dyskinesia.
    Nicholas AP, Lubin FD, Hallett PJ, Vattem P, Ravenscroft P, Bezard E, Zhou S, Fox SH, Brotchie JM, Sweatt JD, Standaert DG.
    J Neurochem; 2008 Jul 30; 106(1):486-94. PubMed ID: 18410512
    [Abstract] [Full Text] [Related]

  • 18. Different levodopa actions on the extracellular dopamine pools in the rat striatum.
    Rodríguez M, Morales I, González-Mora JL, Gómez I, Sabaté M, Dopico JG, Rodríguez-Oroz MC, Obeso JA.
    Synapse; 2007 Feb 30; 61(2):61-71. PubMed ID: 17117421
    [Abstract] [Full Text] [Related]

  • 19. Nondopaminergic mechanisms in levodopa-induced dyskinesia.
    Brotchie JM.
    Mov Disord; 2005 Aug 30; 20(8):919-31. PubMed ID: 16007614
    [Abstract] [Full Text] [Related]

  • 20. [The effect of chronic treatment of deprenyl in animal models of Parkinson's disease].
    Nakashima H, Asari S, Nishimoto A, Goldstein M.
    No To Shinkei; 1991 Apr 30; 43(4):357-61. PubMed ID: 1909537
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.